Cargando…

Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers

Currently, the response to cancer treatments is highly variable, and severe side effects and toxicity are experienced by patients receiving high doses of chemotherapy, such as those diagnosed with triple-negative breast cancer. The main goal of researchers and clinicians is to develop new effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Isaiah A., De Carlo, Flavia, Sitta, Juliana, Varner, William, Howard, Candace M., Claudio, Pier Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053544/
https://www.ncbi.nlm.nih.gov/pubmed/36982548
http://dx.doi.org/10.3390/ijms24065474
_version_ 1785015438859567104
author Edwards, Isaiah A.
De Carlo, Flavia
Sitta, Juliana
Varner, William
Howard, Candace M.
Claudio, Pier Paolo
author_facet Edwards, Isaiah A.
De Carlo, Flavia
Sitta, Juliana
Varner, William
Howard, Candace M.
Claudio, Pier Paolo
author_sort Edwards, Isaiah A.
collection PubMed
description Currently, the response to cancer treatments is highly variable, and severe side effects and toxicity are experienced by patients receiving high doses of chemotherapy, such as those diagnosed with triple-negative breast cancer. The main goal of researchers and clinicians is to develop new effective treatments that will be able to specifically target and kill tumor cells by employing the minimum doses of drugs exerting a therapeutic effect. Despite the development of new formulations that overall can increase the drugs’ pharmacokinetics, and that are specifically designed to bind overexpressed molecules on cancer cells and achieve active targeting of the tumor, the desired clinical outcome has not been reached yet. In this review, we will discuss the current classification and standard of care for breast cancer, the application of nanomedicine, and ultrasound-responsive biocompatible carriers (micro/nanobubbles, liposomes, micelles, polymeric nanoparticles, and nanodroplets/nanoemulsions) employed in preclinical studies to target and enhance the delivery of drugs and genes to breast cancer.
format Online
Article
Text
id pubmed-10053544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100535442023-03-30 Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers Edwards, Isaiah A. De Carlo, Flavia Sitta, Juliana Varner, William Howard, Candace M. Claudio, Pier Paolo Int J Mol Sci Review Currently, the response to cancer treatments is highly variable, and severe side effects and toxicity are experienced by patients receiving high doses of chemotherapy, such as those diagnosed with triple-negative breast cancer. The main goal of researchers and clinicians is to develop new effective treatments that will be able to specifically target and kill tumor cells by employing the minimum doses of drugs exerting a therapeutic effect. Despite the development of new formulations that overall can increase the drugs’ pharmacokinetics, and that are specifically designed to bind overexpressed molecules on cancer cells and achieve active targeting of the tumor, the desired clinical outcome has not been reached yet. In this review, we will discuss the current classification and standard of care for breast cancer, the application of nanomedicine, and ultrasound-responsive biocompatible carriers (micro/nanobubbles, liposomes, micelles, polymeric nanoparticles, and nanodroplets/nanoemulsions) employed in preclinical studies to target and enhance the delivery of drugs and genes to breast cancer. MDPI 2023-03-13 /pmc/articles/PMC10053544/ /pubmed/36982548 http://dx.doi.org/10.3390/ijms24065474 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Edwards, Isaiah A.
De Carlo, Flavia
Sitta, Juliana
Varner, William
Howard, Candace M.
Claudio, Pier Paolo
Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
title Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
title_full Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
title_fullStr Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
title_full_unstemmed Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
title_short Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
title_sort enhancing targeted therapy in breast cancer by ultrasound-responsive nanocarriers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053544/
https://www.ncbi.nlm.nih.gov/pubmed/36982548
http://dx.doi.org/10.3390/ijms24065474
work_keys_str_mv AT edwardsisaiaha enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers
AT decarloflavia enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers
AT sittajuliana enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers
AT varnerwilliam enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers
AT howardcandacem enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers
AT claudiopierpaolo enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers